Surmodics (STU:SU6) Debt-to-Asset : 0.18 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Surmodics Debt-to-Asset?

Surmodics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.9 Mil. Surmodics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €30.0 Mil. Surmodics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €168.2 Mil. Surmodics's debt to asset for the quarter that ended in Mar. 2024 was 0.18.

Surmodics Debt-to-Asset Historical Data

The historical data trend for Surmodics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Debt-to-Asset Chart

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.07

0.09

0.18

Surmodics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.20	0.18	0.18	0.19	0.18

Competitive Comparison of Surmodics's Debt-to-Asset

For the Medical Devices subindustry, Surmodics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surmodics's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Surmodics's Debt-to-Asset falls into.

Surmodics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Surmodics's Debt-to-Asset for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.817	+	30.339)	/	174.032
	=	0.18

Surmodics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.921	+	30.047)	/	168.181
	=	0.18

Surmodics (STU:SU6) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Surmodics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Surmodics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics (STU:SU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (STU:SU6) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SRDX:USA SU6:Germany

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Surmodics (STU:SU6) Headlines

No Headlines